Suggestions
Kate Bingham
Managing Partner at SV Health Investors
Kate Bingham is a prominent figure in the biotech and venture capital industry. She is a Managing Partner at SV Health Investors, where she has been working since 1991.5 Bingham co-leads SV's biotech franchise, which focuses on building companies that develop transformational new medicines and bring drugs from discovery to market.6
Bingham has a distinguished academic background, holding a first-class degree in Biochemistry from the University of Oxford and an MBA from Harvard Business School, where she was a Kennedy Scholar and Baker Scholar.5
Throughout her career, Bingham has made significant contributions to the biotech industry:
- Her investments have resulted in the launch of eight drugs for treating inflammatory and autoimmune diseases and cancer.1
- She has served on the boards of companies in the UK, US, Ireland, Sweden, and Germany.3
- In 2020, Bingham chaired the UK Vaccine Taskforce, leading efforts to find and manufacture COVID-19 vaccines.4
For her services as Chair of the UK Vaccine Taskforce, Bingham was awarded a DBE (Dame Commander of the Order of the British Empire) in the 2021 Queen's Birthday Honours.6 She also serves on the Board of the Francis Crick Institute and ARIA (Advanced Research and Invention Agency).14
Bingham is known for her expertise in building and investing in early-stage biotech companies across the UK, EU, and US.2 Her work has been recognized with several awards, including the 2017 Lifetime Achievement Award from the BioIndustry Association UK.3
Highlights
Congratulations to the founders and founders of Draig Therapeutics from Cardiff- emerging from stealth today. $140m to fund game changing psychiatric treatments. @RuthMcKernan https://t.co/ez5Ll8Cgf6 Welsh biotech wins funding to develop new depression treatments
Exciting opportunity for VCs! Imperial and the Royal Academy of Engineering have launched a pioneering Science and Technology Venture Capital Fellowship. This is NOT an introduction to Venture Capital, but rather an opportunity for mid-career VCs or those with prior investing experience to join a carefully curated group of peers who will be exposed to leading industry professionals and allow for enduring connections within specialised life science and deep tech investing tracks. Designed to run concurrently with a busy work schedule. The fellowship will comprise 20 in-person days over a year – with 2-3 day focused sessions every two months. Any questions to: [email protected] if interested. Application deadline Aug 7th . https://lnkd.in/e-P6SQzC
